Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC

Video

In Partnership With:

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Chemotherapy isn’t particularly critical in the treatment of metastatic CRC, Venook says. What is more important is the choice of biologic in combination with chemotherapy.

There is a suggestion that there is a benefit with cetuximab (Erbitux) in patients with all RAS wildtype CRC in combination with chemotherapy. In a US study though, data showed that bevacizumab (Avastin) and cetuximab are essentially the same in this combination, Venook adds.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD